Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1441-1460 of 1,694 trials

Breast Cancer: Palbociclib and Fulvestrant Study

We are investigating if a new treatment combination can help prevent relapse in patients with ER positive HER2 negative breast cancer. This study focuses on those with detectable tumor DNA during treatment.

ER Positive HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

HER2 Mutated Solid Tumors: Sevabertinib Study

We are studying how well sevabertinib tablets work and their safety for patients with solid tumors that have HER2 mutations. This research may help improve treatment options for these patients.

Pancreatic CancerUrothelial CarcinomaGallbladder Cancer6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineOncology

Chronic Pain After Mastectomy: Comparing Treatments

We are studying the effectiveness of Serratus Plane Block, capsaicin, and botulinum toxin type A for managing chronic neuropathic pain after mastectomy. This trial aims to find out which treatment offers better pain relief for those not helped by standard therapies.

Post-Mastectomy Pain Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurologyOncology

Prostate Cancer: BMS-986365 vs. Standard Treatment

We are comparing a new medication, BMS-986365, to standard treatments for men with metastatic castration-resistant prostate cancer. The study aims to see if the new drug can better delay disease progression and improve overall health.

Metastatic Castration-resistant Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Ovarian Cancer: Relacorilant with Nab-Paclitaxel and Bevacizumab

We are studying a new treatment combination for patients with advanced ovarian, primary peritoneal, or fallopian-tube cancer. The trial aims to evaluate how well this combination works and its safety.

Ovarian, Fallopian Tube, or Peritoneal CancerEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Intranasal Lysine-Aspirin for Respiratory Disease

We are studying the effects of a new nasal treatment on asthma and nasal symptoms in patients with NSAID-exacerbated respiratory disease. The goal is to see if it improves breathing and overall quality of life.

Nonsteroidal Anti-Inflammatory Drug Exacerbated Respiratory Disease (N-ERD)1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Congenital Nephrogenic Diabetes Insipidus: Fluconazole Study

We are testing whether fluconazole can help people with congenital nephrogenic diabetes insipidus reduce excessive urination and improve their quality of life. This study focuses on patients with a specific AVPR2 gene mutation.

Congenital Nephrogenic Diabetes Insipidus≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrology

Opioid Use Disorder: Daridorexant Treatment

We are studying whether daridorexant can help reduce illicit substance use in people with opioid use disorder already on buprenorphine. The trial also looks at improvements in cravings, withdrawal symptoms, and overall treatment retention.

Opioid Use Disorder≤3 monthsEfficacy phase (II)11-15 visitsStandard MedicinesPsychiatry

Type 1 Diabetes: Fenofibrate Study for Children

We are testing whether fenofibrate can help maintain beta cell function in children newly diagnosed with type 1 diabetes. The study also looks at the safety of this medication for young patients.

Type 1 Diabetes1-2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesEndocrinologyPediatrics

Heart Inflammation: Immunosuppressive Treatment Study

We are studying whether a combination of prednisone and azathioprine can improve heart function in patients with inflammatory heart disease. This trial compares the treatment to a placebo to see if it offers any benefits.

Myocarditis>2 yearsMonitoring phase (IV)11-15 visitsStandard MedicinesCardiologyInternal Medicine

Infantile Spasms: Vigabatrin for High-Risk Children

We are studying whether vigabatrin can prevent infantile spasms in children under 1 year old who are at high risk due to conditions like tuberous sclerosis. This research aims to improve outcomes for these vulnerable infants.

High-Risk Infantile Spasm Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurology

Alcohol Use Disorder: Psilocybin Treatment

We are studying if a single dose of psilocybin can help reduce heavy drinking in people with alcohol use disorder. This trial compares the effects of psilocybin to a placebo over 12 weeks.

Alcohol Use Disorder>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Preventing Infections After Hysterectomy: Azithromycin vs. Cefuroxime

We are studying whether a combination of azithromycin and cefuroxime can better prevent infections after hysterectomy compared to cefuroxime alone. This research aims to improve antibiotic use in surgical settings.

Undergoing Hysterectomy>2 yearsMonitoring phase (IV)Investigational MedicinesGynecology and ObstetricsInfectious Diseases

Grass Pollen Allergy: Sublingual Immunotherapy Study

We are evaluating a new sublingual treatment for people with grass pollen allergies to see if it effectively reduces allergy symptoms. The study will also assess the safety of different doses.

Allergic Rhinitis due to PollenEfficacy phase (II)Confirmation phase (III)Investigational MedicinesAllergology

ALK-Positive Advanced Lung Cancer: NVL-655 vs. Alectinib

We are studying a new medication, NVL-655, for patients with advanced ALK-positive lung cancer who haven't been treated before. The goal is to see if it works better and is safer than the current standard treatment, alectinib.

Advanced ALK-positive Non-Small Cell Lung CancerConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

5-Aminolevulinic Acid (5-ALA) for Brain Tumors in Kids

We are studying the safety of 5-ALA during surgeries for children and adolescents with brain tumors. The trial will help us understand how well it identifies tumor cells and its effects on young patients.

Brain Tumor>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Central Retinal Artery Occlusion: Tenecteplase Study

We are investigating whether tenecteplase can help improve vision in patients with central retinal artery occlusion when given shortly after symptoms begin. This study compares it to standard treatment to see which is more effective.

Central Retinal Artery Occlusion>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiologyNeurologyOphthalmology

Cardiovascular Risk: Allopurinol Study

We are investigating if allopurinol can lower cardiovascular risks in patients with high risk, including those experiencing long-COVID. This study focuses on individuals over 60 years old as well.

Heart FailureHypertensionAtrial Fibrillation>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyEndocrinologyInternal Medicine

Papillary Craniopharyngioma: Dabrafenib and Trametinib Treatment

We are studying how well the medications dabrafenib and trametinib reduce tumor size in patients with papillary craniopharyngioma. The trial also looks at how these treatments affect quality of life and other health aspects.

Papillary Craniopharyngioma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Difficult-to-Treat Hypertension: OPTIMAL-HT Study

We are exploring whether a new combination of medications can help people with uncontrolled high blood pressure achieve better control. This study will compare different treatment strategies to find the most effective approach.

High Blood Pressure (Hypertension)OverpressureConfirmation phase (III)Monitoring phase (IV)Standard MedicinesCardiologyInternal Medicine